Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
Identifieur interne : 002626 ( PubMed/Checkpoint ); précédent : 002625; suivant : 002627Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
Auteurs : J. Bonneau [France] ; C. Dumestre-Perard [France] ; M. Rinaudo-Gaujous [France] ; C. Genin [France] ; M. Sparrow [Australie] ; X. Roblin [France] ; S. Paul [France]Source :
- Autoimmunity reviews [ 1873-0183 ] ; 2015.
Descripteurs français
- KwdFr :
- Anticorps (immunologie), Facteur de stimulation des colonies de granulocytes et de macrophages (immunologie), Humains, Maladies inflammatoires intestinales (immunologie), Maladies inflammatoires intestinales (sang), Marqueurs biologiques (sang), Polyosides (immunologie), Protéines liées au GPI (immunologie), Résultat thérapeutique.
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Biomarkers.
- chemical , immunology : Antibodies, GPI-Linked Proteins, Granulocyte-Macrophage Colony-Stimulating Factor, Polysaccharides.
- blood : Inflammatory Bowel Diseases.
- immunology : Inflammatory Bowel Diseases.
- Humans, Treatment Outcome.
Abstract
Traditionally, IBD diagnosis is based on clinical, radiological, endoscopic, and histological criteria. Biomarkers are needed in cases of uncertain diagnosis, or to predict disease course and therapeutic response. No guideline recommends the detection of antibodies (including ASCA and ANCA) for diagnosis or prognosis of IBD to date. However, many recent data suggest the potential role of new serological markers (anti-glycan (ACCA, ALCA, AMCA, anti-L and anti-C), anti-GP2 and anti-GM-CSF Ab). This review focuses on clinical utility of these new serological markers in diagnosis, prognosis and therapeutic monitoring of IBD. Literature review of anti-glycan, anti-GP2 and anti-GM-CSF Ab and their impact on diagnosis, prognosis and prediction of therapeutic response was performed in PubMed/MEDLINE up to June 2014. Anti-glycan, anti-GP2 and anti-GM-CSF Ab are especially associated with CD and seem to be correlated with complicated disease phenotypes even if results differ between studies. Although anti-glycan Ab and anti-GP2 Ab have low sensitivity in diagnosis of IBD, they could identify a small number of CD patients not detected by other tests such as ASCA. Anti-glycan Abs are associated with a progression to a more severe disease course and a higher risk for IBD-related surgery. Anti-GP2 Ab could particularly contribute to better stratify cases of pouchitis. Anti-GM-CSF Ab seems to be correlated with disease activity and could help predict relapses. These new promising biomarkers could particularly be useful in stratification of patients according to disease phenotype and risk of complications. They could be a valuable aid in prediction of disease course and therapeutic response but more prospective studies are needed.
DOI: 10.1016/j.autrev.2014.11.004
PubMed: 25462578
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25462578Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.</title><author><name sortKey="Bonneau, J" sort="Bonneau, J" uniqKey="Bonneau J" first="J" last="Bonneau">J. Bonneau</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Dumestre Perard, C" sort="Dumestre Perard, C" uniqKey="Dumestre Perard C" first="C" last="Dumestre-Perard">C. Dumestre-Perard</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology, UMR 5163, CNRS-UJF, University of Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology, UMR 5163, CNRS-UJF, University of Grenoble</wicri:regionArea><wicri:noRegion>University of Grenoble</wicri:noRegion><wicri:noRegion>University of Grenoble</wicri:noRegion></affiliation></author><author><name sortKey="Rinaudo Gaujous, M" sort="Rinaudo Gaujous, M" uniqKey="Rinaudo Gaujous M" first="M" last="Rinaudo-Gaujous">M. Rinaudo-Gaujous</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Genin, C" sort="Genin, C" uniqKey="Genin C" first="C" last="Genin">C. Genin</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Sparrow, M" sort="Sparrow, M" uniqKey="Sparrow M" first="M" last="Sparrow">M. Sparrow</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, The Alfred Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Roblin, X" sort="Roblin, X" uniqKey="Roblin X" first="X" last="Roblin">X. Roblin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gastroenterology, University of Saint-Etienne</wicri:regionArea><wicri:noRegion>University of Saint-Etienne</wicri:noRegion><wicri:noRegion>University of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Paul, S" sort="Paul, S" uniqKey="Paul S" first="S" last="Paul">S. Paul</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France. Electronic address: stephane.paul@chu-st-etienne.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25462578</idno><idno type="pmid">25462578</idno><idno type="doi">10.1016/j.autrev.2014.11.004</idno><idno type="wicri:Area/PubMed/Corpus">002F89</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F89</idno><idno type="wicri:Area/PubMed/Curation">002F10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F10</idno><idno type="wicri:Area/PubMed/Checkpoint">002F10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.</title><author><name sortKey="Bonneau, J" sort="Bonneau, J" uniqKey="Bonneau J" first="J" last="Bonneau">J. Bonneau</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Dumestre Perard, C" sort="Dumestre Perard, C" uniqKey="Dumestre Perard C" first="C" last="Dumestre-Perard">C. Dumestre-Perard</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology, UMR 5163, CNRS-UJF, University of Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology, UMR 5163, CNRS-UJF, University of Grenoble</wicri:regionArea><wicri:noRegion>University of Grenoble</wicri:noRegion><wicri:noRegion>University of Grenoble</wicri:noRegion></affiliation></author><author><name sortKey="Rinaudo Gaujous, M" sort="Rinaudo Gaujous, M" uniqKey="Rinaudo Gaujous M" first="M" last="Rinaudo-Gaujous">M. Rinaudo-Gaujous</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Genin, C" sort="Genin, C" uniqKey="Genin C" first="C" last="Genin">C. Genin</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Sparrow, M" sort="Sparrow, M" uniqKey="Sparrow M" first="M" last="Sparrow">M. Sparrow</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, The Alfred Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Roblin, X" sort="Roblin, X" uniqKey="Roblin X" first="X" last="Roblin">X. Roblin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University of Saint-Etienne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gastroenterology, University of Saint-Etienne</wicri:regionArea><wicri:noRegion>University of Saint-Etienne</wicri:noRegion><wicri:noRegion>University of Saint-Etienne</wicri:noRegion></affiliation></author><author><name sortKey="Paul, S" sort="Paul, S" uniqKey="Paul S" first="S" last="Paul">S. Paul</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France. Electronic address: stephane.paul@chu-st-etienne.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne</wicri:regionArea><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion><wicri:noRegion>University Hospital of Saint-Etienne</wicri:noRegion></affiliation></author></analytic><series><title level="j">Autoimmunity reviews</title><idno type="eISSN">1873-0183</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies (immunology)</term><term>Biomarkers (blood)</term><term>GPI-Linked Proteins (immunology)</term><term>Granulocyte-Macrophage Colony-Stimulating Factor (immunology)</term><term>Humans</term><term>Inflammatory Bowel Diseases (blood)</term><term>Inflammatory Bowel Diseases (immunology)</term><term>Polysaccharides (immunology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps (immunologie)</term><term>Facteur de stimulation des colonies de granulocytes et de macrophages (immunologie)</term><term>Humains</term><term>Maladies inflammatoires intestinales (immunologie)</term><term>Maladies inflammatoires intestinales (sang)</term><term>Marqueurs biologiques (sang)</term><term>Polyosides (immunologie)</term><term>Protéines liées au GPI (immunologie)</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term><term>GPI-Linked Proteins</term><term>Granulocyte-Macrophage Colony-Stimulating Factor</term><term>Polysaccharides</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Inflammatory Bowel Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps</term><term>Facteur de stimulation des colonies de granulocytes et de macrophages</term><term>Maladies inflammatoires intestinales</term><term>Polyosides</term><term>Protéines liées au GPI</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Inflammatory Bowel Diseases</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Maladies inflammatoires intestinales</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Traditionally, IBD diagnosis is based on clinical, radiological, endoscopic, and histological criteria. Biomarkers are needed in cases of uncertain diagnosis, or to predict disease course and therapeutic response. No guideline recommends the detection of antibodies (including ASCA and ANCA) for diagnosis or prognosis of IBD to date. However, many recent data suggest the potential role of new serological markers (anti-glycan (ACCA, ALCA, AMCA, anti-L and anti-C), anti-GP2 and anti-GM-CSF Ab). This review focuses on clinical utility of these new serological markers in diagnosis, prognosis and therapeutic monitoring of IBD. Literature review of anti-glycan, anti-GP2 and anti-GM-CSF Ab and their impact on diagnosis, prognosis and prediction of therapeutic response was performed in PubMed/MEDLINE up to June 2014. Anti-glycan, anti-GP2 and anti-GM-CSF Ab are especially associated with CD and seem to be correlated with complicated disease phenotypes even if results differ between studies. Although anti-glycan Ab and anti-GP2 Ab have low sensitivity in diagnosis of IBD, they could identify a small number of CD patients not detected by other tests such as ASCA. Anti-glycan Abs are associated with a progression to a more severe disease course and a higher risk for IBD-related surgery. Anti-GP2 Ab could particularly contribute to better stratify cases of pouchitis. Anti-GM-CSF Ab seems to be correlated with disease activity and could help predict relapses. These new promising biomarkers could particularly be useful in stratification of patients according to disease phenotype and risk of complications. They could be a valuable aid in prediction of disease course and therapeutic response but more prospective studies are needed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25462578</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>21</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.</ArticleTitle><Pagination><MedlinePgn>231-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2014.11.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(14)00276-6</ELocationID><Abstract><AbstractText>Traditionally, IBD diagnosis is based on clinical, radiological, endoscopic, and histological criteria. Biomarkers are needed in cases of uncertain diagnosis, or to predict disease course and therapeutic response. No guideline recommends the detection of antibodies (including ASCA and ANCA) for diagnosis or prognosis of IBD to date. However, many recent data suggest the potential role of new serological markers (anti-glycan (ACCA, ALCA, AMCA, anti-L and anti-C), anti-GP2 and anti-GM-CSF Ab). This review focuses on clinical utility of these new serological markers in diagnosis, prognosis and therapeutic monitoring of IBD. Literature review of anti-glycan, anti-GP2 and anti-GM-CSF Ab and their impact on diagnosis, prognosis and prediction of therapeutic response was performed in PubMed/MEDLINE up to June 2014. Anti-glycan, anti-GP2 and anti-GM-CSF Ab are especially associated with CD and seem to be correlated with complicated disease phenotypes even if results differ between studies. Although anti-glycan Ab and anti-GP2 Ab have low sensitivity in diagnosis of IBD, they could identify a small number of CD patients not detected by other tests such as ASCA. Anti-glycan Abs are associated with a progression to a more severe disease course and a higher risk for IBD-related surgery. Anti-GP2 Ab could particularly contribute to better stratify cases of pouchitis. Anti-GM-CSF Ab seems to be correlated with disease activity and could help predict relapses. These new promising biomarkers could particularly be useful in stratification of patients according to disease phenotype and risk of complications. They could be a valuable aid in prediction of disease course and therapeutic response but more prospective studies are needed.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonneau</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumestre-Perard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology, UMR 5163, CNRS-UJF, University of Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaudo-Gaujous</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparrow</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roblin</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, University of Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, University Hospital of Saint-Etienne, France. Electronic address: stephane.paul@chu-st-etienne.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489339">GP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crohn's disease</Keyword><Keyword MajorTopicYN="N">GM-CSF</Keyword><Keyword MajorTopicYN="N">GP2</Keyword><Keyword MajorTopicYN="N">Glycan</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25462578</ArticleId><ArticleId IdType="pii">S1568-9972(14)00276-6</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2014.11.004</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Bonneau, J" sort="Bonneau, J" uniqKey="Bonneau J" first="J" last="Bonneau">J. Bonneau</name></noRegion><name sortKey="Dumestre Perard, C" sort="Dumestre Perard, C" uniqKey="Dumestre Perard C" first="C" last="Dumestre-Perard">C. Dumestre-Perard</name><name sortKey="Genin, C" sort="Genin, C" uniqKey="Genin C" first="C" last="Genin">C. Genin</name><name sortKey="Paul, S" sort="Paul, S" uniqKey="Paul S" first="S" last="Paul">S. Paul</name><name sortKey="Rinaudo Gaujous, M" sort="Rinaudo Gaujous, M" uniqKey="Rinaudo Gaujous M" first="M" last="Rinaudo-Gaujous">M. Rinaudo-Gaujous</name><name sortKey="Roblin, X" sort="Roblin, X" uniqKey="Roblin X" first="X" last="Roblin">X. Roblin</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Sparrow, M" sort="Sparrow, M" uniqKey="Sparrow M" first="M" last="Sparrow">M. Sparrow</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002626 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002626 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25462578
|texte= Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25462578" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |